Abstract: The present invention relates to compounds of the formula I
wherein R1, R2, R3, X, Y and the dashed line are as defined in the specification, to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use as psychotherapeutic agents.
Type:
Grant
Filed:
December 8, 2000
Date of Patent:
July 23, 2002
Assignee:
Pfizer INC
Inventors:
Megan Ann Gibbs, Harry Ralph Howard, Jeffrey Scott Sprouse, Joel Barry Schachter, Phillip Branch Chappell
Abstract: The invention provides methods for inhibiting oxidative degradation of pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient which methods comprise adding an oxidation-inhibiting amount of a ferrous ion source, preferably in the form of a pharmaceuticalexcipient, to the formulation.
The invention further provides pharmaceutical formulations comprising at least one oxidation-susceptible active drug ingredient and an oxidation-inhibiting amount of a ferrous iron source, preferably in the form of a pharmaceuticalexcipient.
The invention still further provides for the use of a ferrous ion source as an anti-oxidant in pharmaceutical formulations.
Abstract: The invention provdes methods of reducing tissue damage resulting from ischemia which comprise administering to a mammal in need of such reduction an effective amount of a combination, or a pharmaceutical composition comprising Such combination, of an NHE-1 inhibitor and a second compound selected from the group consisting of: (a) a complement modulator, (b) a metabolic modulator, (c) an anti-apoptotic agent, (d) a nitric oxide synthase-related agent, and (e) an enzyme/protein modulator.
Abstract: A compound of the formula:
or the pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined above are useful as ORL1-receptor agonists, and useful as analgesics or the like in mammalian subjects.
Abstract: The present invention relates to a method of treating depression, anxiety or psychosis in a mammal, including a human, by administering to the mammal a D4 receptor antagonist in combination with an antidepressant or an anxiolytic agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a D4 receptor antagonist and an antidepressant or an anxiolytic agent.
Type:
Application
Filed:
December 5, 2001
Publication date:
July 18, 2002
Applicant:
Pfizer Inc
Inventors:
Phillip Branch Chappell, Stevin Howard Zorn
Abstract: A polymorph of 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridylsulfonyl}-4-ethylpiperazine.
Type:
Grant
Filed:
July 26, 2001
Date of Patent:
July 16, 2002
Assignee:
Pfizer Inc.
Inventors:
Laurence James Harris, Richard Anthony Storey, Albert Shaw Wood
Abstract: The invention relates to a method of preparing compounds of the formula
and to pharmaceutically acceptable salts thereof. The compounds of formula 1 are antibacterial agents that may be used to treat various bacterial and protozoa infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial protozoa infections by administering the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1 and to intermediates useful in such preparation.
Type:
Grant
Filed:
November 18, 1999
Date of Patent:
July 16, 2002
Assignee:
Pfizer Inc
Inventors:
Brian Scott Bronk, Michael Anthony Letavic, Takushi Kaneko, Bingwei Vera Yang, Edward Alan Glazer, Hengmiao Cheng
Abstract: This invention relates to compounds of the formula 1
and to pharmaceutically acceptable salts, prodrugs and solvates thereof wherein X1, X2, R2 and R6 are as defined herein. The compounds of formula 1 are antibacterial and antiprotozoal agents that may be used to treat various bacterial and protozoal infections and disorders related to such infections. The invention also relates to pharmaceutical compositions containing the compounds of formula 1 and to methods of treating bacterial and protozoal infections by administering the compounds of formula 1.
Type:
Grant
Filed:
September 20, 1999
Date of Patent:
July 16, 2002
Assignee:
Pfizer Inc
Inventors:
Wei-Guo Su, Takushi Kaneko, Yong-Jin Wu
Abstract: The present invention relates to methods of making quinoline amides of Formula I below, which are microsomal triglyceride transfer protein inhibitors and can be used as medicines.
The present invention also relates to compounds that are used to make quinoline amides of Formula I and methods of making these compounds.
Abstract: The present invention provides novel 5-substituted picolinic acid compounds of formula (I) or a pharmaceutically acceptable salt thereof:
wherein R1 and R2 are independently H, C2-C6 acyl or halo-substituted benzoyl; and R3 is —C(O)O—C1-C6 alkyl, C(O)OH, CN, CONH2, CONHCH3, CON(CH3)2, 1-methyltetrazole or 2-methyltetrazole, with the proviso that when R2 is acetyl and R3 is methoxycarbonyl, R1 is not H; and that when R3 is CN, CONH2, CONHCH3, CON(CH3)2, 1-methyltetrazole or 2-methyltetrazole, R1 and R2 are H.
The present invention also relates to a pharmaceutical composition comprising compound of the present invention, which is useful in the treatment of IL-1 and TNF mediated diseases or the like.
The present invention further relates to a process for producing the compounds of the formula (I).
Abstract: The present invention relates to a method of using a compound of the formula (I):
wherein A, X1, X2 and Q are as defined herein, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition thereof, in the treatment of a disease, condition or disorder of the peripheral or central nervous system, including but not limited to Alzheimer's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, migraine, cerebral amyloid angiopathy, AIDS, age-related cognitive decline, mild cognitive impairment and prion diseases.
Type:
Grant
Filed:
September 27, 2000
Date of Patent:
July 9, 2002
Assignee:
Pfizer Inc
Inventors:
Barbara G. Sahagan, Anabella Villalobos
Abstract: Compounds of formula I,
wherein
R1 represents C1-4 alkoxy optionally substituted by one or more fluorine atoms;
R2 and R3 independently represent H or C1-6 alkoxy (which is optionally substituted);
R4 represents a 4-, 5-, 6- or 7-membered heterocyclic ring, the ring being optionally fused to a benzene ring or a 5- or 6-membered heterocyclic, the ring system as a whole being optionally substituted;
X represents CH or N; and
L is absent,
or represents a cyclic group of formula Ia,
or represents a chain of formula Ib,
and pharmaceutically acceptable salts thereof; are useful in therapy, in particular in the treatment of benign prostatic hyperplasia.
Type:
Grant
Filed:
February 7, 2000
Date of Patent:
July 9, 2002
Assignee:
Pfizer, Inc.
Inventors:
David Nathan Abraham Fox, Alan John Collis, Simon John Mantell
Abstract: The present invention provides a compound of the formula:
and its pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5 and m are as defined in claim 1. The present invention also provides processes for the preparation thereof, the use thereof in treating cytokines mediated diseases and/or cell adhesion molecules (CAMs) mediated diseases and pharmaceutical compositions for use in such therapy.
Abstract: Compounds of formula (I):
are antithrombotic agents, having utility in a variety of therapeutic areas including the prevention and/or treatment of deep vein thrombosis (DVT) after surgery, major medical illness, paralysis, malignancy, prolonged immobilisation trauma, application of lower limb plaster casts, or fractures of the lower limbs or pelvis; recurrent DVT; DVT during pregnancy when there is a previous history thereof; reocclusion following thrombolytic therapy; chronic arterial obstruction; peripheral vascular disease; acute myocardial infarction; unstable angina; atrial fibrillation; thrombotic stroke; transient ischaemic attacks; disseminated intravascular coagulation; coagulation in extra-corporeal circuits; occlusion of arterio-venous shunts and blood vessel grafts (including coronary artery by-pass grafts); and restenosis and occlusion following angioplasty.
Type:
Grant
Filed:
September 14, 2000
Date of Patent:
July 9, 2002
Assignee:
Pfizer Inc.
Inventors:
Julian Blagg, Alan Daniel Brown, Elisabeth Colette Louise Gautier, Julian Duncan Smith, Andrew Brian McElroy
Abstract: The invention relates to compounds of the formula
and to pharmaceutically acceptable salts thereof, wherein R1, R2 and Z are as defined herein. The invention also relates to pharmaceutical compositions containing the compounds of formula I and to methods of using said compounds in the treatment of hyperproliferative diseases such as cancer.
Type:
Grant
Filed:
May 19, 1999
Date of Patent:
July 2, 2002
Assignee:
Pfizer Inc
Inventors:
Lee Daniel Arnold, Mikel Paul Moyer, Susan Beth Sobolov-Jaynes
Abstract: This invention is directed to methods, pharmaceutical compositions and kits comprising an aldose reductase inhibitor (ARI), a prodrug thereof or a pharmaceutically acceptable salt of said ARI or said prodrug and a selective COX-2 inhibitor, a prodrug thereof or a pharmaceutically acceptable salt of said selective COX-2 inhibitor or said prodrug. This invention further relates to methods of using those pharmaceutical compositions for the treatment of diabetic complications such as diabetic neuropathy, diabetic nephropathy, diabetic retinopathy and diabetic cardiomyopathy.